Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants had given written informed consent to participate in the study in accordance with local regulations~* Adult participants 18 years and older with a diagnosis of T1DM made at least 1 year prior to informed consent~* Participants were being treated with insulin or insulin analog~* Willing and able to perform self-monitoring of blood glucose (SMBG) and complete the study diary as required per protocol~* At the Screening Visit, A1C was between 7.0% to 11.0%~* Females of childbearing potential used an adequate method of contraception and had a negative pregnancy test~Exclusion Criteria:~* Use of antidiabetic agent other than insulin or insulin analog at the time of screening~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening~* Chronic systemic corticosteroid use~* Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).